Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Boston Scientific IONâ„¢ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data

April 3, 2011 By Bio-Medicine.Org

NATICK, Mass. and NEW ORLEANS, April 3, 2011 /PRNewswire/ —
Boston Scientific Corporation (NYSE:
BSX
) today announced results from a pooled patient-level
analysis of its PERSEUS and TAXUS ATLAS clinical trial data,
demonstrating differences in safety and efficacy outcomes favoring
the next-generation ION™ Platinum Chromium (PtCr)
Paclitaxel-Eluting Stent System (TAXUS® Element™)
compared to the currently available TAXUS® Liberte®
Paclitaxel-Eluting Stent System.  Results were presented at
the American College of Cardiology Annual Scientific Sessions by
Dean Kereiakes, M.D., Medical Director at The Christ Hospital Heart
and Vascular Center and The Lindner Research Center in Cincinnati
and Principal Investigator for the PERSEUS clinical program.

“Although the ION and TAXUS Liberte Stents employ the same drug
and polymer, the ION Stent demonstrated significantly lower rates
of major adverse cardiac events (MACE), target lesion failure (TLF)
and myocardial infarction (MI) in this case-matched analysis of
nearly 2,300 patients,” said Dr. Kereiakes.  “This study
demonstrates that alloy composition, stent design and strut
thickness may influence angiographic and clinical outcomes
following drug-eluting stent deployment.”

The study compared pooled patient-level data from 2,298 patients
enrolled in the PERSEUS (ION Stent) and TAXUS ATLAS (TAXUS Liberte
Stent) trials.  Propensity score matching was performed to
adjust for differences in patient and lesion characteristics
between the groups, and clinical follow-up was conducted out to 12
months.  Propensity-matched results in 1,326 patients revealed
that the ION Stent achieved significantly lower rates of MACE (7.5
percent vs. 12.0 percent, p=0.007) and TLF (5.5 percent vs. 8.5
percent, p=0.04) largely driven by a reduction in myocardial
infarction (1.8 percent vs. 3.9 percent, p=0.

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech